Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
- Status
- TERMINATED
- Phase
- PHASE1
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
- Status
- COMPLETED
- Phase
- PHASE3
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
- Status
- TERMINATED
- Phase
- PHASE2
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
- Status
- COMPLETED
- Phase
- PHASE1
Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2